FDA Approves New Pancreatic Cancer Drug Rasonque

Why it matters locally: This FDA approval provides a new treatment option for Michigan residents diagnosed with metastatic pancreatic cancer, offering potential benefits for patients undergoing care at hospitals across the state.

WASHINGTON – The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) today, introducing a new treatment for metastatic pancreatic cancer. Rasonque functions as a RAS inhibitor, targeting the most common form of the disease. Regulators made the approval several months ahead of their projected schedule. The decision makes Rasonque available to patients with advanced pancreatic cancer.